Novo-owned company sells former Boehringer project

The Swedish drug group Orexo, in which Novo Holdings holds one fourth of the shares, has sold a development program for anti-inflammatory drugs to a newly founded company in Stockholm. Orexo also appoints Novo Holdings CEO Kasim Kutay as head of its nomination committee.

Photo: Orexo/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Omstridt parallelimportør går konkurs

Parallelimportøren Europharma, der to gange i 2017 blev suspenderet af Lægemiddelstyrelsen, er gået konkurs. Selskabet har erkendt, at et varelager for 50 mio. kr. er usælgeligt.

Related articles